Literature DB >> 16705201

Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study.

M Brandt-Christensen1, K Kvist, F M Nilsson, P K Andersen, L V Kessing.   

Abstract

OBJECTIVE: To estimate the risk for persons treated with antidepressants or lithium of subsequent treatment with antiparkinson drugs (APD).
METHODS: The Danish national prescription database supplied data on all persons who received antidepressants, lithium, or antidiabetics (first control group). A second control group was included comprising persons from the general population. Outcome was purchase of APD and the study period was 1995 to 1999.
RESULTS: In total, 1 293 789 persons were included. The rate ratio of treatment with APD after treatment with antidepressants was 2.27 (95% CI 2.14 to 2.42) for men and 1.50 (95% CI 1.43 to 1.58) for women. Figures for lithium were almost identical.
CONCLUSION: Persons treated with antidepressants or lithium are at increased risk of subsequently treatment with APD, showing an association between anxiety/affective disorder and Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705201      PMCID: PMC2077439          DOI: 10.1136/jnnp.2005.083345

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  Depression in Parkinson's disease.

Authors:  D Aarsland; J L Cummings
Journal:  Acta Psychiatr Scand       Date:  2002-09       Impact factor: 6.392

2.  Depression and the risk of neurological disorders.

Authors:  Andres M Kanner
Journal:  Lancet       Date:  2005-10-01       Impact factor: 79.321

3.  Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death.

Authors:  Jihong Xu; Juraj Culman; Annegret Blume; Stephan Brecht; Peter Gohlke
Journal:  Stroke       Date:  2003-04-03       Impact factor: 7.914

4.  Higher incidence of depression preceding the onset of Parkinson's disease: a register study.

Authors:  Albert F G Leentjens; Marjan Van den Akker; Job F M Metsemakers; Richel Lousberg; Frans R J Verhey
Journal:  Mov Disord       Date:  2003-04       Impact factor: 10.338

5.  Increased risk of Parkinson's disease after depression: a retrospective cohort study.

Authors:  A G Schuurman; M van den Akker; K T J L Ensinck; J F M Metsemakers; J A Knottnerus; A F G Leentjens; F Buntinx
Journal:  Neurology       Date:  2002-05-28       Impact factor: 9.910

6.  Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study.

Authors:  F M Nilsson; L V Kessing; T G Bolwig
Journal:  Acta Psychiatr Scand       Date:  2001-11       Impact factor: 6.392

7.  Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study.

Authors:  M Shiba; J H Bower; D M Maraganore; S K McDonnell; B J Peterson; J E Ahlskog; D J Schaid; W A Rocca
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

Review 8.  Neuroprotective effects of lithium in cultured cells and animal models of diseases.

Authors:  De-Maw Chuang; Ren-Wu Chen; Elzbieta Chalecka-Franaszek; Ming Ren; Ryota Hashimoto; Vladimir Senatorov; Hirohiko Kanai; Christopher Hough; Toyoko Hiroi; Peter Leeds
Journal:  Bipolar Disord       Date:  2002-04       Impact factor: 6.744

9.  Untreated depression and hippocampal volume loss.

Authors:  Yvette I Sheline; Mokhtar H Gado; Helena C Kraemer
Journal:  Am J Psychiatry       Date:  2003-08       Impact factor: 18.112

10.  Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.

Authors:  Michael R Littner; Clete Kushida; W McDowell Anderson; Dennis Bailey; Richard B Berry; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Teofilo Lee-Chiong; Kasey K Li; Daniel L Loube; Timothy Morgenthaler; Merrill Wise
Journal:  Sleep       Date:  2004-05-01       Impact factor: 5.849

View more
  8 in total

1.  Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency.

Authors:  Jacqueline Hoeppner; Lara Prudente-Morrissey; Sabine Christiane Herpertz; Reiner Benecke; Uwe Walter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-09-19       Impact factor: 5.270

2.  The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.

Authors:  Carol A Lazzara; Rebeccah R Riley; Anand Rane; Julie K Andersen; Yong-Hwan Kim
Journal:  Brain Res       Date:  2015-06-26       Impact factor: 3.252

Review 3.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 4.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

5.  Use of antidepressants and the risk of Parkinson's disease: a prospective study.

Authors:  A Alonso; L A García Rodríguez; G Logroscino; M A Hernán
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06       Impact factor: 10.154

6.  Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study.

Authors:  Fang Fang; Qun Xu; Yikyung Park; Xuemei Huang; Albert Hollenbeck; Aaron Blair; Arthur Schatzkin; Freya Kamel; Honglei Chen
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

7.  Use of antipsychotics and long-term risk of parkinsonism.

Authors:  Angelo d'Errico; Elena Strippoli; Rosario Vasta; Gianluigi Ferrante; Stefania Spila Alegiani; Fulvio Ricceri
Journal:  Neurol Sci       Date:  2021-10-15       Impact factor: 3.830

8.  Prescribing cascades in community-dwelling adults: A systematic review.

Authors:  Ann S Doherty; Faiza Shahid; Frank Moriarty; Fiona Boland; Barbara Clyne; Tobias Dreischulte; Tom Fahey; Seán P Kennelly; Emma Wallace
Journal:  Pharmacol Res Perspect       Date:  2022-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.